In vitro evolution of ribozymes capable of site-specific histone acetylation
In vitro evolution of ribozymes capable of site-specific histone acetylation
批准号:
8308862
负责人:
Jonathan Thomas Sczepanski
金额:
$4.92万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-01 至 2014-03-31
关键词:
Acetyl Coenzyme AAcetylationAcetyltransferaseBiological AssayCatalytic RNACellsChromatinChromatin ModelingChromatin StructureDNA RepairDNA biosynthesisDevelopmentDiseaseEngineeringEnzymesEpigenetic ProcessEventEvolutionGene Expression ProfileGene SilencingGenetic TranscriptionHistone AcetylationHistone H4HistonesIn VitroIndividualLeadLinkLysineMammalian CellMass Spectrum AnalysisMethodsModificationN-terminalNuclearNucleosome Core ParticleNucleosomesPatternPeptidesPhysical condensationProcessProteinsRNARegulationResearchResearch PersonnelRoleSiteStructureTailTechnologyTranscriptTranscriptional RegulationU6 small nuclear RNAWestern Blottingbasecancer cellcancer therapyhistone acetyltransferasehistone modificationin vivoinsightnovelnovel diagnosticspromoterthioestertooltumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The posttranslational acetylation of histone proteins is a crucial regulator of chromatin structure and function. Furthermore, global abnormalities in histone acetylation patterns occur early during the course of tumorigenesis, suggesting they may be relevant steps in the transformation process. However, the epigenetic role of particular histone acetylation events, and the mechanisms leading to their dysregulation in diseases, is poorly understood. Further elucidation of the precise role of histone acetylation will require new,
orthogonal tools that allow researchers to study single acetylation events in vivo. The proposed research will employ in vitro evolution methods to develop ribozymes that site-specifically acetylate histone proteins in cells. Histone H4 lysine 16 (H4K16) will be the initial target due to
the potent effect of this residue on the structure and function of chromatin. Peptides derived from the N-terminal tail of histone H4 will serve as in vitro substrates during evolution, and ribozymes will be selected based on their ability to acetylate these peptides at lysine 16. Individual ribozyme clones from the final round of selection will be assayed for acetyltransferase activity in the context of free histone proteins, nucleosome core particles, and nucleosomal arrays. Competent ribozymes will be engineered for increased stability against cellular degradation and expressed in cells using a cassette base on the high copy number U6 snRNA promoter. In vivo acetylation of H4K16 will be verified by Western blot and mass spectrometry analysis of endogenous histone proteins isolated from cells expressing histone acetyltransferase (HAT) ribozymes. In addition, a comprehensive transcriptome analysis will be conducted on cells expressing HAT ribozymes. Ribozymes developed using these methods will allow researchers to study H4K16 acetylation, as well as the enzymes associated with this modification, with greater analytical precision compared to approaches that are currently achievable. Such studies may lead to new diagnostics and therapies for cancer. In addition, the proposed selection strategy may eventually be used to evolve HAT ribozymes that target other histone residues or even non- histone proteins.
PUBLIC HEALTH RELEVANCE: Global abnormalities in histone acetylation patterns appear early and accumulate during the course of tumorigenesis and are a common hallmark of cancer cells (1). A detailed explanation for these phenomena (and insight into possible treatment options) is impeded by the limited availability of tools for studying histone acetylation (2,3). Th proposed research aims to develop a novel tool that will allow researchers to study histone acetylation with greater analytical precision compared to approaches that are currently achievable. !
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An L-Aptamer-Displacement Assay for High-Throughput Screening of RNA-Targeted Small Molecule Antivirals
-
批准号:10648368
-
项目类别:
-
资助金额:$16.71万
-
财政年份:2023
-
负责人:Jonathan Thomas Sczepanski
-
依托单位:
CLAP-seq: An Aptamer-Based Platform for Transcriptome-Wide Mapping of RNA Modifications
-
批准号:9812571
-
项目类别:
-
资助金额:$17.76万
-
财政年份:2019
-
负责人:Jonathan Thomas Sczepanski
-
依托单位:
Mirror Image Aptamers: Next Generation RNA-Binding Reagents for Basic Research and Therapeutic Applications
-
批准号:9382491
-
项目类别:
-
资助金额:$36.24万
-
财政年份:2017
-
负责人:Jonathan Thomas Sczepanski
-
依托单位:
Mirror Image Aptamers: Next Generation RNA-Binding Reagents for Basic Research and Therapeutic Applications
-
批准号:10001546
-
项目类别:
-
资助金额:$35.59万
-
财政年份:2017
-
负责人:Jonathan Thomas Sczepanski
-
依托单位:
Mirror Image Aptamers: Next Generation RNA-Binding Reagents for Basic Research and Therapeutic Applications
-
批准号:10240632
-
项目类别:
-
资助金额:$35.52万
-
财政年份:2017
-
负责人:Jonathan Thomas Sczepanski
-
依托单位:
In vitro evolution of ribozymes capable of site-specific histone acetylation
-
批准号:8462476
-
项目类别:
-
资助金额:$5.22万
-
财政年份:2012
-
负责人:Jonathan Thomas Sczepanski
-
依托单位:
海外基金